Central Serous Chorioretinopathy: Etiology, Course and Prognosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Stefan Sacu, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT01378130
First received: June 20, 2011
Last updated: April 25, 2013
Last verified: April 2013
  Purpose

Pathogenesis of central serous chorioretinopathy is not entirely understood yet, therefore further investigations are needed. During this study patients with an acute episode of central serous chorioretinopathy are observed with established ophthalmologic methods (multimodal imagine) every 6 weeks until subretinal fluid is reabsorbed to gain further insides in etiology, course and prognosis of this disease.


Condition
Central Serous Chorioretinopathy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis

Resource links provided by NLM:


Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • Clinical Outcome [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    OCT, Visus


Secondary Outcome Measures:
  • Subclinical Data [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    FA findings, retinal sensitivity in Microperimetry, contrast sensitivity, Amsler Grid Test


Enrollment: 50
Study Start Date: April 2011
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Detailed Description:

Patients with central serous chorioretinopathy are recruited from the Department of Ophthalmology at the Medical University of Vienna. All patients undergo ETDRS visual acuity measurement, Pelli-Robson contrast examination, Amsler-Grid testing, questionnaire testing, ophthalmologic examination, SD-OCT and polarization-sensitive OCT, fundus autofluorescence, fluorescein angiography, indocyanine-green angiography, fundus photo and microperimetry. Patients are re-examined after an interval of 6 weeks until subretinal fluid is entirely reabsorbed to gain further insides in etiology, course and prognosis of this disease.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with an acute episode of central serous chorioretinopathy are recruited from the Department of Ophthalmology at the Medical University of Vienna.

Criteria

Inclusion Criteria:

  • Signed informed consent form
  • Age over 18 years
  • acute episode of Central Serous Chorioretinopathy
  • Symptoms for less than two weeks
  • no treatment on study eye

Exclusion Criteria:

  • bad compliance
  • protected patient group (pregnant women)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01378130

Locations
Austria
Vienna Gerenal Hospital
Vienna, Austria
Sponsors and Collaborators
Medical University of Vienna
Investigators
Principal Investigator: Stefan Sacu, Ass.Prof.Dr. Department of Ophthalmology, Medical University of Vienna, Austria
  More Information

No publications provided

Responsible Party: Stefan Sacu, Assoc. Prof. Dr., Medical University of Vienna
ClinicalTrials.gov Identifier: NCT01378130     History of Changes
Other Study ID Numbers: EK 180/2011
Study First Received: June 20, 2011
Last Updated: April 25, 2013
Health Authority: Austria: Agency for Health and Food Safety

Keywords provided by Medical University of Vienna:
CCS
CSC
Subretinal Fluid
multimodal imaging

Additional relevant MeSH terms:
Central Serous Chorioretinopathy
Retinal Diseases
Eye Diseases

ClinicalTrials.gov processed this record on September 29, 2014